Krebs Biochemicals & Industries Limited

CIN: L24110AP1991PLC103912



Date: 27-09-2023

To, The Manager, Department of Corporate Relations, BSE Limited, P J Towers, Dalal Street, Fort, Mumbai- 400001. Scrip Code : 524518 To, The Manager, Listing Department, National Stock Exchange of India Ltd, Exchange Plaza, Bandra Kurla Complex, Bandra(E), Mumbai- 400051. **Scrip Code : KREBSBIO**

Dear Sir / Madam,

Sub: Outcome / Proceedings of the 31st Annual General Meeting

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, please find enclosed the summary of proceedings of the 31st Annual General Meeting of the Company which was held on Wednesday, 27th September, 2023 at the Registered office of the Company at Kothapalli (Village), Kasimkota (Mandal), Anakapalli, Vishakapatnam (District), Andhra Pradesh — 531031.

Kindly take the above information on record.

For Krebs Biochemicals and Industries Limited

Rohit Taparia Company Secretary & Compliance Officer Email:com_sec@krebsbiochem.com



SUMMARY PROCEEDINGS OF THE 31ST ANNUAL GENERAL MEETING OF THE MEMBERS OF THE COMPANY HELD ON WEDNESDAY, 27TH SEPTEMBER, 2023

- a. The 31st Annual General Meeting of members of Krebs Biochemicals and Industries Limited was held at the Registered office of the Company at Kothapalli (Village), Kasimkota (Mandal), Anakapalli, Vishakapatnam (District), Andhra Pradesh 531031 at 11:30 a.m.
- b. All the Directors including Chairman of the Audit and Nomination & Remuneration Committee of the Board, Chief Financial Officer and the Company Secretary were present at the Meeting.
- c. The representatives of the Statutory Auditors Ms. Kavitha Padmini, Mr. D S M Ram, Secretarial Auditors, Ms. Kritika Sharma, Scrutinizer were also present at the meeting.
- d. Dr. R T Ravi, Chairman presided over the meeting and addressed the members at the 31st Annual General Meeting of the Company.
- e. After introducing other Directors present on dias, the Chairman informed the members that all the Statutory Registers are available at the meeting venue for inspection by the members present at the meeting.
- f. With the consent of the members, the notice convening the 31st Annual General Meeting was taken as read.
- g. The Chairman then read the Chairman's speech.
- h. The Chairman informed that pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Companies (Management and Administration) Rules as amended and Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the company has provided electronic voting facility to the members entitled to cast their vote at the Annual General Meeting. The e-voting process was carried out by the company from 24th September, 2023 from 9.00 AM to 26th September, 2023 till 5.00 PM with cut-off date determining shareholders entitled to vote being 20th September, 2023.

He also informed that facility will be provided to vote by Ballot to those members who are present at the meeting and have not cast their vote electronically.

Krebs Biochemicals & Industries Limited

CIN: L24110AP1991PLC103912



- i. He informed that Ms. Kritika Sharma, Practicing Company Secretary who was appointed as the Scrutinizer to scrutinize the remote e-voting process including voting by ballot at this meeting is present at the meeting.
- j. He informed that the results of the voting will be declared after the report of the scrutinizer is received and shall be posted on the website of the Company and shall be displayed on the notice board of the Company at its registered office.
- k. The Chairman then requested the members to raise their questions, if any.
- I. The questions raised were answered by the Chairman, Managing Director/CFO and the Executive Director.
- m. The Chairman thereafter informed the members that the following items on the agenda as stated in the notice of this Annual General Meeting requires the approval of the members.

ORDINARY BUSINESS:

- 1. To receive, consider, approve and adopt the Audited Balance Sheet, the Statement of Profit & Loss and Cash Flow Statement for the financial year ended March 31 2023 together with the Notes attached thereto along with the Reports of Auditors and Directors thereon.
- 2. To appoint a director in place of Mr. Jitendra Shah (holding DIN- 09377846), who retires by rotation and being eligible, offers himself for re-appointment.
- **3.** To appoint a director in place of Mr. Avinash Ravi (holding DIN- 01616152), who retires by rotation and being eligible, offers himself for re-appointment.

SPECIAL BUSINESS:

- 4. Appointment of Mr. Jitendra Shah (DIN- 09377846) as Managing Director / CEO of the Company.
- 5. Continuation of Dr. R T Ravi (DIN: 00272977) as a Non-executive Director of the Company.
- 6. Approval for Related Party Transactions with Ipca Laboratories Limited.



- 7. To ratify the remuneration of the Cost Auditors for the financial year ending March 31, 2024.
- n. The Chairman thanked the members for the support to the Company and declared the meeting as closed.

The meeting started at 11.30 a.m. and closed at 12.02 p.m.

This is for your information and records please.

Thanking you,

Yours Faithfully, For **Krebs Biochemicals and Industries Limited**

Rohit Taparia Company Secretary & Compliance Officer Email:com_sec@krebsbiochem.com